Home / Business and Economy / Potato Glut: Weight-Loss Drugs Sink Spud Sales
Potato Glut: Weight-Loss Drugs Sink Spud Sales
1 Apr
Summary
- UK farmers face surplus due to declining demand.
- Weight-loss injections cut potato consumption significantly.
- Surplus potatoes may become animal feed or donated.
A significant surplus of potatoes is accumulating in the United Kingdom, leaving farmers like Andy Goodacre with unsold crops. Goodacre is facing the potential loss of approximately 600 tons of potatoes valued at $158,000. This situation stems from a declining demand for traditional staples, influenced by healthier eating trends and the widespread use of weight-loss injections such as Ozempic and Mounjaro.
The appetite-suppressing effects of these medications are directly reducing consumption, impacting both grocery sales and restaurant orders. Andrew Crook of the National Federation of Fish Friers notes that customers are now ordering smaller portions. Farmers worry that if they cannot profit this year, future harvests could be reduced as growers switch to more profitable crops. The stored potatoes risk spoiling by early April, prompting discussions about donating the surplus to food banks or using it for cattle feed.
In the United States, American chain restaurants are also adapting by rethinking portion sizes in response to GLP-1 weight-loss medications. Chains like Shake Shack and Chipotle are offering high-protein, lower-carb menus, while Olive Garden introduced a "lighter portion" menu. Obesity specialists confirm that patients find previously normal restaurant portions now overwhelming, highlighting a widespread shift in eating habits.
